In MDS, FLT3 mutations are observed in high-risk subgroups and are associated with complex karyotype (30,31). NPM1 and FLT3 mutations are found primarily in AML; however, the presence of these mutations in an MDS patient should alert the clinician about the risk of rapid progression to AML (22). This evidence concerns the gene FLT3 and acute myeloid leukemia.